Medline Inc (MDLN) Stock Forecast & Price Target

Medline has demonstrated strong financial performance with a significant sales revenue increase of 11.47% year-over-year, rising from $25.51 billion to $28.43 billion for the 12 months ending December 2025. The company has also shown improvement in its return on capital, which increased from 7.22% to 7.44%, while new customer signings totaled $2.4 billion in 2025, highlighting robust demand for Medline-branded products and solutions. Furthermore, the Medline Brand now constitutes close to half of the company's revenue, with segment net sales rising by 10% year-over-year to $13.7 billion, indicative of strong volume gains and successful expansion efforts in key product areas.

The financial outlook for Medline appears negative, mainly due to a significant decline in Economic Profit, which dropped by 220.79% year-over-year from a gain of $345.1 million to a loss of $416.9 million post-IPO. Additionally, Net Operating Profit After Tax (NOPAT) decreased by 12.66% year-over-year, falling from $2.45 billion to $2.14 billion, while Economic Operating Cash Flow (EBITDAR) contracted by 4.48% year-over-year, decreasing from $3.71 billion to $3.54 billion. Given the pressures from low margins in the healthcare sector, along with increased competition and potential supply chain disruptions, the company faces significant operational challenges that could adversely affect revenue generation.